相关实验视频
Updated: Jun 3, 2025

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
Published on: July 18, 2016
卵巢状细胞癌:临床病理学特征,预后和免疫治疗结果
Tianyu Zhang1, Jie Yang2, Sijian Li1
1Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, National Clinical Research Center for Obstetric & Gynecologic Diseases, Beijing, China.
卵巢状细胞癌 (SCC) 的预后不好,其阶段和年龄会影响生存率. 免疫检查点抑制剂 (ICI) 显示出潜在的益处,特别是对于高瘤突变负担 (TMB) 的患者.
科学领域:
- 在瘤学瘤学.
- 妇科瘤学 妇科瘤学
- 癌症研究 癌症研究
背景情况:
- 卵巢状细胞癌 (SCC) 是一种罕见的恶性瘤,对其特征和存活率的数据有限.
- 了解预后因素和治疗疗效对于改善患者的治疗结果至关重要.
研究的目的:
- 为了描述卵巢SCC,分析生存结果,并评估免疫检查点抑制剂 (ICI) 的有效性.
- 在卵巢SCC中确定整体生存 (OS) 和无进展生存 (PFS) 的预后预测因子.
主要方法:
- 在2000年至2023年间诊断的42名卵巢SCC患者的回顾性分析.
- 卡普兰-梅尔方法用于OS和PFS分析; 考克斯比例危险模型用于单变量和多变量分析.
- 评估分子特征,包括瘤突变负担 (TMB) 和特定基因突变.
主要成果:
- 平均生存期为42.0个月;平均PFS为26.9个月. 一年的OS和PFS率分别为73.7%和57.5%.
- 晚期疾病和年轻的诊断年龄与更糟糕的生存率有关.
- 五名患者接受了辅助性ICI和化疗,其中4人没有治疗后出现疾病迹象.
结论:
- 卵巢SCC有不利的预后,阶段和年龄作为重要的预测因素.
- 免疫检查点抑制剂 (ICI) 可能为卵巢SCC患者提供生存益处.
- 高瘤突变负担 (TMB) 可能预测在卵巢SCC中对ICI的更好的反应.
更多相关视频
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
10:35An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
Published on: November 28, 2010
相关概念视频
Tumor Immunotherapy
Cancer Survival Analysis
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...